Cramer Speculates in CV Therapeutics
by Jon C. Ogg
24/7 Wall St.
On tonight's (Friday) Mad Money on CNBC, Jim Cramer had his normal 'Speculation Friday' and talked CV Therapeutics (CVTX) for a speculative biotech in with Acadia (ACAD) and Nastech (NSTK). Cramer said CVTX is a huge battle ground stock that makes small molecule drugs. Last month it had 36% of the float short, but he thinks the bearish case just doesn't hold up. Cramer thinks the stock could explode into the $20's because of earnings, or it could get acquired and go there. Its Ranexa drug for angina is the driver now, but it could get approved as a diabetic treatment down the road. It has a drug up for potential approval next year to detect cardiac disease. Cramer said it could fetch $20.00 to $36.00 per share if it was to be acquired.
Speculators and biotech investors should know that this one does lose money and it is expected to keep losing money: -$2.95 EPS for fiscal 2007 and expected to post -$1.31 in 2008 fiscal EPS.
Continue article at 247WallSt.com
RELATED READING:
- Cramer's Three Biotech Picks, And His Biotech Strategy
- Cramer's Obesity Stock Plays
247WallSt.com is a regular contributor to BioHealth Investor.com
__________________
24/7 Wall St.
On tonight's (Friday) Mad Money on CNBC, Jim Cramer had his normal 'Speculation Friday' and talked CV Therapeutics (CVTX) for a speculative biotech in with Acadia (ACAD) and Nastech (NSTK). Cramer said CVTX is a huge battle ground stock that makes small molecule drugs. Last month it had 36% of the float short, but he thinks the bearish case just doesn't hold up. Cramer thinks the stock could explode into the $20's because of earnings, or it could get acquired and go there. Its Ranexa drug for angina is the driver now, but it could get approved as a diabetic treatment down the road. It has a drug up for potential approval next year to detect cardiac disease. Cramer said it could fetch $20.00 to $36.00 per share if it was to be acquired.
Speculators and biotech investors should know that this one does lose money and it is expected to keep losing money: -$2.95 EPS for fiscal 2007 and expected to post -$1.31 in 2008 fiscal EPS.
Continue article at 247WallSt.com
RELATED READING:
- Cramer's Three Biotech Picks, And His Biotech Strategy
- Cramer's Obesity Stock Plays
247WallSt.com is a regular contributor to BioHealth Investor.com
__________________
posted by Nico at
9:19 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home